ASCO26: AstraZeneca's AZD-3470 demonstrates PRMT5 inhibitor safety for cHL patients

At ASCO 2026, AstraZeneca unveiled initial clinical data for AZD-3470 in relapsed/refractory classical Hodgkin lymphoma. At ASCO 2026, AstraZeneca unveiled initial clinical data for AZD-3470 in relapsed/refractory classical Hodgkin lymphoma. Credit: Shutterstock/ Dragon Images On 30 May at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, AstraZeneca released the first safety and efficacy data of AZD-3470, in its Phase I PRIMAVERA (NCT06137144) study for relapsed/refractory (R/R) classical Hodgkin Lymphoma (cHL). AZD-3470 is an inhibitor of protein arginine methyltransferase 5 (PRMT5), which becomes upregulated upon epigenetic silencing of methylthioadenosine phosphorylase (MTAP), observed in more than 80% of cHL patients.…

Source: Clinical Trials Arena